Volume 24, Number 3—March 2018
Research
Use of Influenza Risk Assessment Tool for Prepandemic Preparedness
Table 2
R = 1† | R = 7‡ | R = 10§ | |||||||
---|---|---|---|---|---|---|---|---|---|
R |
W × R |
R |
W × R |
R |
W × R |
||||
Disease severity and pathogenesis | 0.2929 | 9.00 | 2.64 | 2.64 | 2.64 | ||||
Population immunity | 0.1929 | 9.00 | 1.74 | 1.74 | 1.74 | ||||
Human infections | 0.1429 | 5.00 | 0.71 | 0.71 | 0.71 | ||||
Antiviral drug and treatment options | 0.1096 | 5.40 | 0.59 | 0.59 | 0.59 | ||||
Antigenic relatedness | 0.0846 | 6.00 | 0.51 | 0.51 | 0.51 | ||||
Receptor binding | 0.0646 | 6.70 | 0.43 | 0.43 | 0.43 | ||||
Genomic variation | 0.0479 | 8.60 | 0.41 | 0.41 | 0.41 | ||||
Transmission in lab animals | 0.0336 | 1.00 | 0.03 | 7.00 | 0.24 | 10.00 | 0.34 | ||
Global distribution in animals | 0.0211 | 1.00 | 0.02 | 0.02 | 0.02 | ||||
Infection in animals |
0.0100 |
6.00 |
0.06 |
0.06 |
0.06 |
||||
Total | 1.0001 | 7.14 | 7.35 | 7.45 |
*IRAT, Influenza Risk Assessment Tool; R, average risk point score; W, weight.
†Substituting the lowest possible risk score (1) to calculate summary IRAT score.
‡Substituting a moderate risk score (7) to calculate summary IRAT score.
§Substituting the highest possible risk score (10) to calculate summary IRAT score.
Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.